

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: **Yoshiji YAMADA, et al.**

Serial Number: **Not Yet Assigned**
(§371 of International Application PCT/JP03/03477)

Filed: **December 21, 2004**

For: **METHOD OF DIAGNOSING RISK OF MYOCARDIAL INFARCTION**

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

December 21, 2004


Sir:

In compliance with 37 CFR 1.56, Applicants call to the attention of the Patent and Trademark Office the references listed on the attached PTO-1449 and cited in the enclosed international search report. Each of references AE-BC is discussed in the specification. Each of references BD-BG is cited in the international search report.

A copy each of references AE-BF is enclosed herewith.

In the event there are any fees due in connection with the filing of this paper, please charge Deposit Account No. 01-2340.

Respectfully submitted,
ARMSTRONG, KRATZ, QUINTOS,
HANSON & BROOKS, LLP


James E. Armstrong, IV
Attorney for Applicants
Reg. No. 42,266

JAM/jaz
Atty. Docket No. **040677**
Suite 1000
1725 K Street, N.W.
Washington, D.C. 20006
(202) 659-2930



23850

PATENT TRADEMARK OFFICE

Enclosures: PTO-1449; References (28); International Search Report

10/517605

T05 Rec'd PCT/PTO 21 DEC 2004

INFORMATION DISCLOSURE STATEMENT PTO-1449	Atty. Docket No. 040677	Serial No. New Application
	Applicant(s): Yoshiji YAMADA, et al.	
	Filing Date: December 21, 2004	Group Art Unit: Not Yet Assigned

U.S. PATENT DOCUMENTS

Examiner Initial	Document No.	Name	Date	Class	Subclass	Filing Date (If appropriate)
_____	AA					
_____	AB					

FOREIGN PATENT DOCUMENTS

Document No.	Date	Country	Translation (Yes or No)
_____	AC		
_____	AD		

OTHER DOCUMENTS

_____	AE ✓	M.E. Marenberg, et al.; "Genetic Susceptibility to Death From Coronary Heart Disease in a Study of Twins;" <i>The New England Journal of Medicine</i> ; Vol. 330; No. 15; April 14, 1994; pp. 1041-1046.		
_____	AF ✓	J.J. Nora, et al.; "Genetic-Epidemiologic Study of Early-onset Ischemic Heart Disease;" <i>Circulation</i> ; Vol. 61; No. 3; March 1980; pp. 503-508.		
<table border="1"> <tr> <td>Examiner</td> <td>Date Considered</td> </tr> </table>			Examiner	Date Considered
Examiner	Date Considered			

INFORMATION DISCLOSURE STATEMENT PTO-1449	Atty. Docket No. 040677	Serial No. New Application
	Applicant(s): Yoshiji YAMADA, et al.	
	Filing Date: December 21, 2004	Group Art Unit: Not Yet Assigned

OTHER DOCUMENTS

_____	AG	U. Broeckel, et al.; "A comprehensive linkage analysis for myocardial infarction and its related risk factors;" <i>Nature Genetics</i> ; Vol. 30; February 2002; pp. 210-214.
_____	AH	F. Cambien, et al.; "Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction;" <i>Nature</i> ; Vol. 359; October 15, 1992; pp. 641-644.
_____	AI	E. J. Weiss, et al.; "A Polymorphism of a Platelet Glycoprotein Receptor as an Inherited Risk Factor for Coronary Thrombosis;" <i>The New England Journal of Medicine</i> ; Vol. 334; No. 17; April 25, 1996; pp. 1090-1094.
_____	AJ	L. Iacoviello, et al.; "Polymorphisms in the Coagulation Factor VII Gene and the Risk of Myocardial Infarction;" <i>The New England Journal of Medicine</i> ; Vol. 338; No. 2; January 8, 1998; pp. 79-85.
_____	AK	J.A. Kuivenhoven, et al., "The Role of a Common Variant of the Cholesteryl Ester Transfer Protein Gene in the Progression of Coronary Atherosclerosis;" <i>The New England Journal of Medicine</i> ; Vol. 338; No. 2; January 8, 1998; pp. 86-93.
_____	AL	M. Boerma, et al.; "A genetic polymorphism in connexin 37 as a prognostic marker for atherosclerotic plaque development;" <i>Journal of Internal Medicine</i> ; Vol. 246; 1999; pp. 211-218.
_____	AM	N. Inoue, et al.; "Polymorphism of the NADH/NADPH Oxidase <i>p22 phox</i> Gene in Patients With Coronary Artery Disease;" <i>Circulation</i> ; Vol. 97; 1998; pp. 135-137.
_____	AN	E.J. Topol, et al; "Single Nucleotide Polymorphisms in Multiple Novel Thrombospondin Genes May Be Associated With Familial Premature Myocardial Infarction;" <i>Circulation</i> ; Vol. 104; November 27, 2001; pp. 2641-2644.
_____	AO	T. Skoog, et al.; "A common functional polymorphism (C→A substitution at position - 863) in the promotor region of the tumour necrosis factor- α (TNF- α) gene associated with reduced circulating levels of TNF- α ;" <i>Human Molecular Genetics</i> ; Vol. 8; No. 8; 1999; pp. 1443-1449.
_____	AP	Y. Yamada, et al.; "Identification of the G ⁹⁹⁴ →T Missense Mutation in Exon 9 of the Plasma Platelet-Activating Factor Acetylhydrolase Gene as an Independent Risk Factor for Coronay Artery Disease in Japanese Men;" <i>Metabolism</i> ; Vol. 47; No. 2; February 1998; pp. 177-181.
Examiner		
Date Considered		

INFORMATION DISCLOSURE STATEMENT PTO-1449	Atty. Docket No. 040677	Serial No. New Application
	Applicant(s): Yoshiji YAMADA, et al.	
	Filing Date: December 21, 2004	Group Art Unit: Not Yet Assigned

OTHER DOCUMENTS

_____	AQ	W. Koch, et al.; "Interleukin-10 and tumor necrosis factor gene polymorphisms and risk of coronary artery disease and myocardial infraction;" <i>Artherosclerosis</i> ; Vol. 159; 2001; pp. 137-144.
_____	AR	I. Inoue, et al.' "A Nucleotide Substitution in the Promotor of Human Angiotensinogen Is Associated with Essential Hypertension and Affects Basal Transcription In Vitro;" <i>J. Clin. Invest</i> ; Vol. 99; No. 7; April 1997; pp. 1786-1797.
_____	AS	J.-C. Lambert, et al.; "Independent association of an APOE gene promoter polymorphism with increased risk of myocardial infarction and decreased APOE plasma concentrations-the ECTIM study;" <i>Human Molecular Genetics</i> ; Vol. 9; No. 1; 2000; pp. 57-61.
_____	AT	M. Eto, et al.; "Increased frequencies of apolipoprotein ε2 and ε4 alleles in patients with ischemic heart disease;" <i>Clinical Genetics</i> ; Vol. 36; 1989; pp. 183-188.
_____	AU	J. Ruiz, et al.; "Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes;" <i>The Lancet</i> ; Vol. 346; September 30, 1995; pp. 869-872.
_____	AV	M. Murata, et al.; "Coronary Artery Disease and Polymorphisms in a Receptor Mediating Shear Stress-Dependent Platelet Activation;" <i>Circulation</i> ; Vol. 96; No. 10; November 18, 1997; pp. 3281-3286.
_____	AW	P. Eriksson, et al.; "Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction;" <i>Proc. Natl. Acad. Sci. USA</i> ; Vol 92; March 1995; pp. 1851-1855.
_____	AX	S. Ye, et al.; "Preliminary report: genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis;" <i>Br Heart J</i> ; Vol. 73; 1995; pp. 209-215.
_____	AY	R.W. Mahley; "Apolipoprotein E: Cholesterol Transport Protein with Expanding Role in Cell Biology;" <i>Science</i> ; Vol 240; April 29, 1988; pp. 622-630.
Examiner _____ Date Considered _____		

INFORMATION DISCLOSURE STATEMENT PTO-1449	Atty. Docket No. 040677	Serial No. New Application
	Applicant(s): Yoshiji YAMADA, et al.	
	Filing Date: December 21, 2004	Group Art Unit: Not Yet Assigned

OTHER DOCUMENTS

_____	AZ	W.J. Schneider, et al.; "Familial Dysbetalipoproteinemia. Abnormal Binding of Mutant Apoprotein E to Low Density Lipoprotein Receptors of Human Fibroblasts and Membranes from Liver and Adrenal of Rats, Rabbits, and Cows;" <i>J. Clin. Invest.</i> ; Vol. 68; November 1981; pp. 1075-1085.		
_____	BA	R.E. Gregg, et al.; "Type III Hyperlipoproteinemia: Defective Metabolism of an Abnormal Apolipoprotein E;" <i>Science</i> ; Vol. 211; February 6, 1981; pp. 584-586.		
_____	BB	J.L. Breslow, et al.; "Studies of familial type III hyperlipoproteinemia using as a genetic marker the apoE phenotype E2/2;" <i>Journal of Lipid Research</i> ; Vol. 23; 1982; pp. 1224-1235.		
_____	BC	P.M. Sullivan, et al.; "Type III Hyperlipoproteinemia and Spontaneous Atherosclerosis in Mice Resulting from Gene Replacement of Mouse <i>ApoE</i> with Human <i>APOE*2</i> ;" <i>The Journal of Clinical Investigation</i> ; Vol. 102; No. 1; July 1998; pp. 130-135.		
_____	BD	S.S. Kumari, et al.; "Functional Expression and Biophysical Properties of Polymorphic Variants of the Human Gap Junction Protein Connexin37;" <i>Biochemical and Biophysical Research Communications</i> ; Vol. 274; No. 1; 2000; pp. 216-224.		
_____	BE	E. Dupont, et al.; "Altered Connexin Expression in Human Congestive Heart Failure;" <i>J Mol Cell Cardiol</i> ; Vol. 33; 2001; pp. 359-371.		
_____	BF	S. Kumari, et al.; "Two Polymorphic Variants of Human Connexin37 Exhibit Different Biophysical Properties;" <i>Molecular Biology of the Cell</i> ; Vol. 9 (Suppl.); November 1998; pp. 93a 538.		
_____	BG	K.E. Reed, et al.; "Molecular cloning and functional expression of human connexin37, an endothelial cell gap junction protein;" <i>J. Clin. Invest.</i> ; Vol. 93; No. 2; 1993; pp. 997-1004.		
<table border="1" style="width: 100%;"> <tr> <td style="width: 40%;">Examiner</td> <td style="width: 60%;">Date Considered</td> </tr> </table>			Examiner	Date Considered
Examiner	Date Considered			